Tags

Type your tag names separated by a space and hit enter

Mepolizumab for the treatment of severe eosinophilic asthma.
Am J Health Syst Pharm 2017; 74(13):963-969AJ

Abstract

PURPOSE

Published data on the pharmacology, pharmacokinetics and pharmacodynamics, and clinical efficacy and safety of the interleukin-5 antagonist mepolizumab are reviewed.

SUMMARY

Asthma of the eosinophilic phenotype is characterized by persistent eosinophilic airway inflammation promoted primarily by T-helper type 2 cytokines, the key regulator of eosinophils. Patients with severe eosinophilic asthma are burdened by the need to administer high doses of corticosteroids to help manage their symptoms. In November 2015, mepolizumab (Nucala, GlaxoSmithKline) gained U.S. marketing approval for use as an add-on maintenance treatment for severe eosinophilic asthma in patients 12 years of age or older, making it the first personalized targeted therapy for this population. Efficacy results from clinical trials provided evidence of the corticosteroid-sparing effects of mepolizumab and its ability to reduce both blood and sputum eosinophil counts. Safety data from several Phase II or III studies involving a total of more than 1,300 patients indicated that mepolizumab was generally well tolerated, and types and rates of adverse events in mepolizumab recipients were comparable to those reported with placebo use; the only mepolizumab-associated serious adverse drug events were asthma exacerbations in 2 patients. The recommended dosage of mepolizumab is 100 mg administrated via subcutaneous injection every 4 weeks.

CONCLUSION

Mepolizumab is a safe and efficacious novel add-on therapy for a small subgroup of patients with severe eosinophilic asthma whose asthma is not adequately controlled by standard regimens for asthma treatment.

Authors+Show Affiliations

Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL. mara_poulakos@pba.edu.University of Utah, Salt Lake City, UT.VA Medical Center, West Palm Beach, FL.Walgreens, West Palm Beach, FL.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28645995

Citation

Poulakos, Mara N., et al. "Mepolizumab for the Treatment of Severe Eosinophilic Asthma." American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists, vol. 74, no. 13, 2017, pp. 963-969.
Poulakos MN, Cargill SM, Waineo MF, et al. Mepolizumab for the treatment of severe eosinophilic asthma. Am J Health Syst Pharm. 2017;74(13):963-969.
Poulakos, M. N., Cargill, S. M., Waineo, M. F., & Wolford, A. L. (2017). Mepolizumab for the treatment of severe eosinophilic asthma. American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists, 74(13), pp. 963-969. doi:10.2146/ajhp160291.
Poulakos MN, et al. Mepolizumab for the Treatment of Severe Eosinophilic Asthma. Am J Health Syst Pharm. 2017 Jul 1;74(13):963-969. PubMed PMID: 28645995.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mepolizumab for the treatment of severe eosinophilic asthma. AU - Poulakos,Mara N, AU - Cargill,Shawna M, AU - Waineo,Melissa F, AU - Wolford,Allen L,Jr PY - 2017/6/25/entrez PY - 2017/6/25/pubmed PY - 2019/5/24/medline KW - antiasthmatic agents KW - asthma KW - eosinophils KW - interleukin-5 KW - mepolizumab KW - monoclonal antibodies SP - 963 EP - 969 JF - American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists JO - Am J Health Syst Pharm VL - 74 IS - 13 N2 - PURPOSE: Published data on the pharmacology, pharmacokinetics and pharmacodynamics, and clinical efficacy and safety of the interleukin-5 antagonist mepolizumab are reviewed. SUMMARY: Asthma of the eosinophilic phenotype is characterized by persistent eosinophilic airway inflammation promoted primarily by T-helper type 2 cytokines, the key regulator of eosinophils. Patients with severe eosinophilic asthma are burdened by the need to administer high doses of corticosteroids to help manage their symptoms. In November 2015, mepolizumab (Nucala, GlaxoSmithKline) gained U.S. marketing approval for use as an add-on maintenance treatment for severe eosinophilic asthma in patients 12 years of age or older, making it the first personalized targeted therapy for this population. Efficacy results from clinical trials provided evidence of the corticosteroid-sparing effects of mepolizumab and its ability to reduce both blood and sputum eosinophil counts. Safety data from several Phase II or III studies involving a total of more than 1,300 patients indicated that mepolizumab was generally well tolerated, and types and rates of adverse events in mepolizumab recipients were comparable to those reported with placebo use; the only mepolizumab-associated serious adverse drug events were asthma exacerbations in 2 patients. The recommended dosage of mepolizumab is 100 mg administrated via subcutaneous injection every 4 weeks. CONCLUSION: Mepolizumab is a safe and efficacious novel add-on therapy for a small subgroup of patients with severe eosinophilic asthma whose asthma is not adequately controlled by standard regimens for asthma treatment. SN - 1535-2900 UR - https://www.unboundmedicine.com/medline/citation/28645995/Mepolizumab_for_the_treatment_of_severe_eosinophilic_asthma_ L2 - https://academic.oup.com/ajhp/article-lookup/doi/10.2146/ajhp160291 DB - PRIME DP - Unbound Medicine ER -